盈健醫療(01419.HK)中期純利1690萬港元 同比增長437.3%
格隆匯2月24日丨盈健醫療(01419.HK)宣佈,截至2020年12月31日止6個月,公司收益2.3億港元,同比減少9.5%;毛利1.09億港元,同比減少7.3%;毛利率由2020財年中期約46.1%增加至約47.2%;公司擁有人應占溢利1690萬港元,同比增長437.3%;每股基本盈利約為4.5港仙。
公司全科醫療服務產生的收益由2020財年中期減少約2710萬港元或16.8%至2021財年中期約1.345億港元。該減少乃主要由於疫情爆發的不利影響導致醫務中心全科醫療服務的病人就診次數減少所致,由預防服務、檢測和外展服務的收益增加所抵銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.